Clinical Trial and Development Support Infrastructure through the DTx Platform Business
First written in FY2022-Q2. 12 of 13 entries say "Restated". Latest entry: 2026-08-07.
No other company in this theme has enough history to compare yet.
- 2026-08-07RestatedEarnings
「We operate 2 businesses: the DTx product business, which comprises the development and marketing of therapeutic apps and medical devices, and the DTx platform business, which comprises the provision of general-purpose clinical trial systems and automated machine-learning analysis systems, as well as support for DTx development using these systems.」
The 2-business structure of the DTx product business and DTx platform business was reiterated. - FY2026-H1RestatedAnnual report
「The Company operates two businesses: the DTx Product Business, which develops therapeutic applications, and the DTx Platform Business, which consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system and supporting DTx development using these systems.」
The two-business structure of the DTx Product Business and the DTx Platform Business, consisting of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support, continues. - FY2025-H1RestatedAnnual report
「The Company operates two businesses: the DTx Product Business, which develops therapeutic applications, and the DTx Platform Business, which consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system and supporting DTx development using these systems.」
The two-business structure of the DTx Product Business and the DTx Platform Business, consisting of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support, continues. - FY2024-Q3RestatedAnnual report
「In this environment, the Company has established the vision of “pursuing sustainable healthcare through the use of ICT” and operates the DTx Product Business, which develops therapeutic applications using its proprietary digital healthcare platform, and the DTx Platform Business, which consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system and supporting DTx development using these systems.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2024-Q2RestatedAnnual report
「In this environment, the Company has established the vision of “pursuing sustainable healthcare through the use of ICT” and operates the DTx Product Business, which develops therapeutic applications using its proprietary digital healthcare platform, and the DTx Platform Business, which consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system and supporting DTx development using these systems.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2024-Q1RestatedAnnual report
「In this environment, the Company has established the vision of “pursuing sustainable healthcare through the use of ICT” and operates the DTx Product Business, which develops therapeutic applications using its proprietary digital healthcare platform, and the DTx Platform Business, which consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system and supporting DTx development using these systems.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2023RestatedAnnual report
「The Company has two segments: ① the DTx Product Business, which develops therapeutic applications, and ② the DTx Platform Business, which consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support using these systems.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2023-Q3RestatedAnnual report
「This segment consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system, as well as supporting DTx development using these systems.」
The same explanation of the components of the DTx Platform Business continues as before. - FY2023-Q2RestatedAnnual report
「The Company has established the vision of “pursuing sustainable healthcare through the use of ICT” and operates the DTx Product Business, which provides in-house-developed therapeutic applications to patients and healthcare professionals, and the DTx Platform Business, which provides pharmaceutical companies with a general-purpose clinical trial system and an automated machine-learning analysis system and supports DTx development.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2023-Q1RestatedAnnual report
「In this environment, the Company has established the vision of “pursuing sustainable healthcare through the use of ICT” and operates the DTx Product Business, which provides in-house-developed therapeutic applications to patients and healthcare professionals, and the DTx Platform Business, which provides pharmaceutical companies with a general-purpose clinical trial system and an automated machine-learning analysis system and supports DTx development. The Company is pursuing these businesses with the aim of creating new value in the industry and solving social issues through the application of blockchain and AI (artificial intelligence) technologies.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2022RestatedAnnual report
「The Company has two segments: ① the DTx Product Business, which develops its own therapeutic applications, and ② the DTx Platform Business, which consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support using these systems.」
The explanation that the DTx Platform Business consists of a general-purpose clinical trial system, an automated machine-learning analysis system and DTx development support continues. - FY2022-Q3RestatedAnnual report
「This segment consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system, as well as supporting DTx development using these systems.」
The same explanation of the components of the DTx Platform Business continues as before. - FY2022-Q2First statedAnnual report
「This segment consists of providing a general-purpose clinical trial system and an automated machine-learning analysis system, as well as supporting DTx development using these systems.」
The general-purpose clinical trial system, automated machine-learning analysis system and DTx development support are described as the core components of the Platform Business.